first_img Alex Hogan/STAT By Ed Silverman May 18, 2018 Reprints [email protected] Tags drug pricesLitigationpatentspharmaceuticalspharmalittleSTAT+ Ed Silverman GET STARTED Pharmalot @Pharmalot Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Log In | Learn More center_img STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is ambitious. We hope to noodle around the Pharmalot grounds, visit the Pharmalot ancestors and take in another installment of our ‘Let’s-see-them-before-they-die‘ concert series. And what about you? This is, as we regularly remind you, a fine time to enjoy the great outdoors. Perhaps, you could catch up on your reading or make time for someone special. Or you could tune out the real world and watch the Royal Wedding. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…Amgen (AMGN) will charge $6,900 a year for a new drug that can spare migraine sufferers a few headaches each month, a price well below Wall Street expectations as the company hopes to avoid payer backlash that has hamstrung recent drug launches, STAT reports. The drug, called Aimovig, is meant for patients who experience at least four migraines per month. There are roughly 24 million patients in the U.S. who would be candidates for treatment. The Institute for Clinical and Economic R, a nonprofit that assesses the value of medicines, pegged cost effectiveness at $8,500. What is it? About the Author Reprints Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. What’s included? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug last_img read more

first_img The incidence rate of prostate cancer is 9-10/100000 population, higher compared to countries like Asia, Africa, lower compared to US, EuropeIn observance of Prostate Cancer Awareness month i.e September, Indian Council of Medical Research (ICMR) has released data on the incidence rate of prostate cancer in India. It states that the incidence rate of prostate cancer is 9-10/100000 population, higher compared to countries like Asia and Africa, but lower compared to the US and Europe. Hence, experts suggest going for complete physical examination including DRE in order to detect prostate cancer at an early stage.Prostate cancer affects the prostate gland which is situated distal to the bladder neck. It is commonly seen in men above the age of 60. Typically, the symptoms are a frequent urge to urinate, painful urination, repeated urinary tract infections (UTI) and occasionally blood in the urine. Surgical treatment includes open surgery (open radical prostatectomy) that is the surgical removal of the prostate gland or minimal invasive surgery (MIS)- robot-assisted radical prostatectomy (RALP). The additional benefits of the later are precision surgery, less blood loss and reduced pain with a short hospital stay and early return to work.Dr Jagdeesh Kulkarni, Prof of Uro-oncology, Asian Cancer Institute, said, “People above the age of 60 are at an increased risk of suffering from prostate cancer. One of the best ways for early detection of prostate cancer is DRE and the prostate-specific antigen (PSA) blood test. Those people who have a family history of prostate cancer, irrespective of the symptoms should undergo regular check-ups including DRE and PSA, after the age of 45.”“Furthermore, it is recommended to embrace a healthy lifestyle, cessation of smoking, well-balanced diet and regular physical exercises would go a long way in keeping prostate cancer at bay,” concluded Dr Kulkarni. Share Read Article Comments (0) News The missing informal workers in India’s vaccine story cancerDREIndian Council of Medical Researchopen radical prostatectomyProstate Cancerprostate glandPSArepeated urinary tract infectionsrobot-assisted radical prostatectomy Indraprastha Apollo Hospitals releases first “Comprehensive Textbook of COVID-19” Related Posts WHO tri-regional policy dialogue seeks solutions to challenges facing international mobility of health professionals Menopause to become the next game-changer in global femtech solutions industry by 2025 ICMR releases data on incidence rate of prostate cancer in India Phoenix Business Consulting invests in telehealth platform Healpha By EH News Bureau on September 25, 2019 Heartfulness group of organisations launches ‘Healthcare by Heartfulness’ COVID care app Add Comment MaxiVision Eye Hospitals launches “Mucormycosis Early Detection Centre”last_img read more